US Patent

US10730895 — Carbidopa prodrug

Composition of Matter · Assigned to AbbVie Inc · Expires 2035-10-21 · 9y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects carbidopa prodrugs, pharmaceutical combinations, and methods for treating Parkinson's disease using these compounds.

USPTO Abstract

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Drugs covered by this patent

Patent Metadata

Patent number
US10730895
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-10-21
Drug substance claim
Yes
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.